Doravirine/lamivudine/tenofovir

Last updated

Doravirine/lamivudine/tenofovir
Combination of
Doravirine Non-nucleoside reverse transcriptase inhibitor
Lamivudine Nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil Nucleotide reverse transcriptase inhibitor
Clinical data
Trade names Delstrigo
Other namesMK-1439A
AHFS/Drugs.com Monograph
MedlinePlus a618049
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. [4] [6] It contains doravirine, lamivudine, and tenofovir disoproxil. [7] [6] It is taken by mouth. [4]

In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018. [7] [8] [9]

References

  1. ↑ "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : DELSTRIGO" (PDF). Pdf.hres.ca. Retrieved 5 June 2022.
  2. ↑ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada . 14 October 2020. Retrieved 17 April 2024.
  3. ↑ "Delstrigo 100 mg /300 mg /245 mg film-coated tablets - Summary of Product Characteristics (SmPC)". Medicines.org.uk. 8 July 2020. Retrieved 1 October 2020.
  4. 1 2 3 "Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 10 October 2019. Retrieved 31 July 2020.
  5. ↑ "Delstrigo EPAR". European Medicines Agency (EMA). 21 September 2018. Retrieved 1 October 2020.
  6. 1 2 Canadian Agency for Drugs and Technologies in Health (June 2019). "Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo)". CADTH Common Drug Reviews. Ottawa (ON). PMID   31393687.
  7. 1 2 "FDA Approves Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and Pifeltro (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. 30 August 2018.
  8. ↑ "Delstrigo approval letter" (PDF). Food and Drug Administration (FDA). 30 August 2018. Archived from the original (PDF) on 21 March 2019. Retrieved 10 September 2019.
  9. ↑ "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Archived from the original on 1 October 2020. Retrieved 22 September 2020.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.